What Omniscient Neurotechnology does
Omniscient Neurotechnology (o8t) builds Quicktome, a platform that uses AI to analyse millions of data points from MRI and resting-state functional MRI scans and produce a connectomic map of a patient's brain network, supporting pre-surgical planning for tumour removal and other neurological procedures. The company says its work underpins 93 peer-reviewed publications, 301 citations and 37 US patents, with clinical endorsements from neurosurgeons at Macquarie University and the University of Miami. Omniscient was founded in Sydney in December 2019 by Stephen Scheeler, Dr Michael Sughrue and Dr Stephane Doyen.
Omniscient Neurotechnology is a healthcare tool on Falcoscan. AI brain-mapping platform that helps neurosurgeons plan safer operations. Falcoscan rates Omniscient Neurotechnology with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Omniscient Neurotechnology is founded in 2019, currently at Series_d_plus stage. Pricing: Paid.